drugset / Trial / NCT02647671

Aquamin and Prevention of Colon Cancer

NCT02647671

Phase 1 Completed 36 enrolled James Varani
RandomizedParallel-groupDouble-blindPrevention

Summary

In the proposed study, investigators will conduct a 90-day dietary intervention study in human subjects. Thirty individuals at risk for adenomatous colon polyp formation will be randomized to receive a calcium and multi-mineral-rich natural product (Aquamin) or a comparable level of calcium alone. There will also be a placebo group. Prior to ingesting the study agents and following the course of treatment, colonic biopsies will be obtained by sigmoidoscopy and quantitatively examined for markers of growth and differentiation. In this study, metabolomic and microbial profiles will also be generated from fecal and colon mucosal samples taken at baseline and study endpoint.

Timeline

Start
2016-04
Primary completion
2021-03
Completion
2021-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aquamin Other / unclassified Oral
Comparator Calcium carbonate Other / unclassified Oral

Indications